KalVista Pharmaceuticals (KALV) Cash from Operations (2014 - 2025)
KalVista Pharmaceuticals (KALV) reported Cash from Operations of 54502000.0 for Q3 2025, down 35.51% on a YoY basis from 84511929.99 in Q3 2024, and down 35.03% sequentially from 40364000.0 in Q2 2025.
KalVista Pharmaceuticals (KALV) Cash from Operations (2014 - 2025) Analysis & Trends
KalVista Pharmaceuticals (KALV) has 12 years of Cash from Operations data on file, last reported at 54502000.0 in Q3 2025.
- For the quarter ending Q3 2025, Cash from Operations fell 35.51% year-over-year to 54502000.0; the trailing twelve-month figure through Jul 2025 stood at 174728000.0 (down 70.1% YoY), and the FY2025 full-year result was 152907000.0, down 71.36% from the prior year.
- Cash from Operations fell to 54502000.0 in Q3 2025, from 40364000.0 in the prior quarter.
- In the past five years, Cash from Operations ranged from a high of 7586000.0 in Q1 2021 to a low of 54502000.0 in Q3 2025.
- A 5-year average of 24221388.89 and a median of 21615000.0 in 2022 frame the typical range for Cash from Operations.
- Peak annual rise in Cash from Operations reached 42.13% in 2021, while the deepest fall reached 394.29% in 2021.
- Tracing KALV's Cash from Operations over 5 years: stood at 19545000.0 in 2021, then dropped by 5.37% to 20594000.0 in 2022, then advanced by 3.73% to 19825000.0 in 2023, then slumped by 99.96% to 39642000.0 in 2024, then sank by 37.49% to 54502000.0 in 2025.
- Business Quant data shows KALV's Cash from Operations at 54502000.0 in Q3 2025, 40364000.0 in Q2 2025, and 39642000.0 in Q4 2024.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -19.59 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -2.49 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 201.34 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.43 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 1.08 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -354.17 Mn |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -54.50 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -54.50 Mn |
| Jul 31, 2025 | -54.50 Mn |
| Apr 30, 2025 | -40.36 Mn |
| Apr 30, 2025 | -40.36 Mn |
| Oct 31, 2024 | -39.64 Mn |
| Oct 31, 2024 | -39.64 Mn |
| Jul 31, 2024 | -40.22 Mn |
| Jul 31, 2024 | -40.22 Mn |
| Apr 30, 2024 | -15.11 Mn |
| Apr 30, 2024 | -15.11 Mn |
| Jan 31, 2024 | -27.57 Mn |
| Jan 31, 2024 | -27.57 Mn |
| Oct 31, 2023 | -19.83 Mn |
| Oct 31, 2023 | -19.83 Mn |
| Jul 31, 2023 | -26.73 Mn |
| Jul 31, 2023 | -26.73 Mn |
| Apr 30, 2023 | -22.64 Mn |
| Apr 30, 2023 | -22.64 Mn |
| Jan 31, 2023 | -9.29 Mn |
| Jan 31, 2023 | -9.29 Mn |